SAIL: Phase II Results of Ara-c and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE™) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML

SAIL: Phase II Results of Ara-c and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE™) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML

Learn More